Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Douthat, W. G.
Right arrow Articles by Cannata Andia, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Douthat, W. G.
Right arrow Articles by Cannata Andia, J. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1994) 9: 1431-1434
© 1994 European Renal Association-European Dialysis and Transplant Association

research-article

Treatment of aluminium intoxication: a new scheme for desferrioxamine administration

W. G. Douthat1, G. Acu{nsim}a Aguerre1, J. L. Fernández Martin1, R. Mouzo2 and J. B. Cannata Andia1,

1Bone and Mineral Research Unit, Hospital Central de Asturias, Universidad de Oviedo 2Renal Unit, Hospital Camino de Santiago, Ponferrada, Espa{nsim}a

Correspondence and offprint requests to: Correspondence and offprint requests to: Dr J. B. Cannata, Servicio de Metabolismo Oseo y Mineral Unidad de Investigaciòn, Hospital Central de Asturias, Apdo 243. (33080) Oviedo

In order to control aluminium toxicity in dialysis patients it is preferable to prevent or limit exposure to it. However, it is sometimes necessary to remove the aluminium by the use of appropriate techniques. The collateral effects of desferrioxamine have led us to test new forms of administering desferrioxamine and attempt to reduce the dose.

The aim of this study was to compare the removal of aluminium by administration of 15 mg/kg of desferrioxamine under two different schemes, that is, 44 h before the dialysis (classic scheme) and 1 h before dialysis (new scheme). The study was carried out in 10 patients over a period of 4 weeks. Aluminium removal was quantified in the dialysate throughout the dialysis. Measurement was also performed of the serum aluminium changes that occurred during the study.

The total removal of aluminium was determined over three consecutive dialysis sessions following the administration of desferrioxamine. A similar amount of aluminium was found under both schemes. However, in the case of those patients given desferriox amine 1 h prior to dialysis, removal of aluminium induced significantly lower serum aluminium peaks: (P<0.02).

These results suggest that the administration of desferrioxamine 1 h before dialysis is a valid alternative to the classic scheme (44 h before). The removal of aluminium at lower increments in the serum aluminium entails less risk for patients.

Keywords: aluminium; chelating therapy; chronic renal failure; desferrioxamine; dialysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
P. Menendez-Fraga, J. L. Fernandez-Martin, E. Blanco-Gonzalez, and J. B. Cannata-Andia
Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration
Clin. Chem., June 1, 1998; 44(6): 1262 - 1268.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.